Press Releases

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels DENVER and CHICAGO, June 12, 2023 –   TriSalus Life Sciences® Inc.,  (TriSalus or the Company), an oncology company in the process of
June 12, 2023
DENVER and FORT LAUDERDALE, Fla., April 20, 2023  –  TriSalus Life Sciences® Inc.,  (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC)
April 20, 2023
*** MEDIA ADVISORY *** PHOENIX, February 28, 2023  –  TriSalus Life Sciences® Inc.,  (“TriSalus” or the “company”), an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, will participate
February 28, 2023
Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors DENVER and CHICAGO, February 16, 2023  – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going
February 16, 2023

Subscribe to Email Alerts

Get news delivered directly to your in box